Clinical Trials Directory

Trials / Completed

CompletedNCT00090584

Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

Behavior Enhances Drug Reduction of Incontinence

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
307 (actual)
Sponsor
Carelon Research · Academic / Other
Sex
Female
Age
21 Years
Healthy volunteers
Accepted

Summary

The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.

Conditions

Interventions

TypeNameDescription
DRUGTolterodine4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
BEHAVIORALBehavioral trainingTraining in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.

Timeline

Start date
2004-08-01
Primary completion
2005-12-01
Completion
2006-08-01
First posted
2004-08-31
Last updated
2013-06-17
Results posted
2013-06-17

Locations

9 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00090584. Inclusion in this directory is not an endorsement.

Behavior Enhances Drug Reduction of Incontinence (BE-DRI) (NCT00090584) · Clinical Trials Directory